AnaptysBio, Inc.
ANAB
$26.58
$0.240.91%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 17.16M | 14.96M | 12.94M | 10.69M | 10.29M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.16M | 14.96M | 12.94M | 10.69M | 10.29M |
| Cost of Revenue | 132.28M | 122.13M | 113.32M | 101.24M | 88.80M |
| Gross Profit | -115.13M | -107.17M | -100.38M | -90.55M | -78.51M |
| SG&A Expenses | 41.95M | 41.08M | 39.77M | 37.26M | 33.44M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 174.23M | 163.21M | 153.09M | 138.50M | 122.24M |
| Operating Income | -157.07M | -148.25M | -140.15M | -127.81M | -111.95M |
| Income Before Tax | -163.62M | -147.80M | -143.99M | -136.70M | -128.70M |
| Income Tax Expenses | -4.00K | 24.00K | 24.00K | 24.00K | 24.00K |
| Earnings from Continuing Operations | -163.62 | -147.82 | -144.02 | -136.72 | -128.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -163.62M | -147.82M | -144.02M | -136.72M | -128.72M |
| EBIT | -157.07M | -148.25M | -140.15M | -127.81M | -111.95M |
| EBITDA | -156.42M | -147.58M | -139.47M | -127.13M | -111.28M |
| EPS Basic | -6.07 | -5.41 | -5.19 | -4.85 | -4.58 |
| Normalized Basic EPS | -3.62 | -3.38 | -3.24 | -3.03 | -2.79 |
| EPS Diluted | -6.08 | -5.43 | -5.20 | -4.85 | -4.58 |
| Normalized Diluted EPS | -3.62 | -3.38 | -3.24 | -3.03 | -2.79 |
| Average Basic Shares Outstanding | 107.71M | 109.57M | 111.32M | 112.89M | 112.65M |
| Average Diluted Shares Outstanding | 107.71M | 109.57M | 111.32M | 112.89M | 112.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
